Abstract: Systems and methods are provided for quality control for biological testing. One embodiment is a system that includes a liquid handler that applies samples of genetic material to a test plate comprising an array of wells, a Polymerase Chain Reaction (PCR) device that amplifies the genetic material, and an analysis device that determines, based on a change in visual appearance of each well, a numerical value indicating whether a corresponding sample is representative of a disease state. The system also includes a quality assurance server that identifies a pattern of the numerical values, and determines a likelihood of the pattern. In an event that the likelihood is less than a threshold value, the quality assurance server flags the test plate as potentially contaminated, and in an event that the likelihood exceeds the threshold value, the quality assurance server refrains from flagging the test plate as potentially contaminated.

Abstract: Systems and methods are provided for quality control for biological testing. One embodiment is a system that includes a liquid handler that applies samples of genetic material to a test plate comprising an array of wells, a Polymerase Chain Reaction (PCR) device that amplifies the genetic material, and an analysis device that determines, based on a change in visual appearance of each well, a numerical value indicating whether a corresponding sample is representative of a disease state. The system also includes a quality assurance server that identifies a pattern of the numerical values, and determines a likelihood of the pattern. In an event that the likelihood is less than a threshold value, the quality assurance server flags the test plate as potentially contaminated, and in an event that the likelihood exceeds the threshold value, the quality assurance server refrains from flagging the test plate as potentially contaminated.

Abstract: Provided are methods of using bromodomain-containing protein 9 inhibitor (I-BRD9) or a derivative thereof in preparation of anti-epileptic drugs. The I-BRD9 has significant effects on anticonvulsion, prolonging of convulsion latency, and reduction of seizure level, and can be used for preparing anti-epileptic drug preparations.

Abstract: Provided are methods of using bromodomain-containing protein 9 inhibitor (I-BRD9) or a derivative thereof in preparation of anti-epileptic drugs. The I-BRD9 has significant effects on anticonvulsion, prolonging of convulsion latency, and reduction of seizure level, and can be used for preparing anti-epileptic drug preparations.